A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2014

Primary Completion Date

May 11, 2015

Study Completion Date

May 11, 2015

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

semaglutide

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

DRUG

placebo

Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.

Trial Locations (1)

Novo Nordisk Investigational Site, Neuss